CSLLY - Arcturus Therapeutics' Lung Disease Candidate Triggers Bullish Rating Analyst Sees Over 200% Upside | Benzinga
Canaccord Genuity has initiated coverage on Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT), a player in the genetic medicine space.
Analysts Whitney Ijem and Joohwan Kim note that the company has developed proprietary and differentiated LNP delivery tech (LUNAR) and novel mRNA cargos (UNA, saRNA), allowing for options based on the application; hence, Arcturus has a pipeline of medicines across a range of indications.
Canaccord Genuity is particularly excited about ARCT-032, the company's inhaled mRNA therapeutic candidate for cystic fibrosis (CF).
Amidst the whirlwind of activities surrounding Arcturus, ARCT-032 seems to have operated quietly, progressing through Phase 1 and now administering doses to CF patients in ...